<DOC>
	<DOCNO>NCT01884623</DOCNO>
	<brief_summary>To test whether cetuximab improve efficacy/tolerance compare methotrexate first line treatment unfit patient ³ 70 year old recurrent /or metastatic HNSCC . Efficacy assess failure free survival</brief_summary>
	<brief_title>Phase III Trial Comparing Methotrexate Cetuximab First-line Treatment Recurrent and/or Metastatic Squamous Cell Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patients age 70 Included ELANONCOVAL study consider `` Unfit '' geriatric evaluation do study PS &lt; 3 Histologically confirm diagnosis squamous cell carcinoma head neck : oral cavity , oropharynx , hypopharynx , larynx . Recurrence and/or metastatic disease suitable local therapy . At least one measurable lesion ( RECIST 1.1 ) CT MRI . No brain metastasis . Clearance creatinine &gt; = 50ml/mn ( MDRD ) . Adequate haematological function define follow : absolute neutrophil count &gt; 1.5 x 109/l , platelet &gt; 100 x 109/l , hemoglobin &gt; = 9.5 g/dl Adequate hepatic function serum total bilirubin &lt; 1.25 Upper limit normal range ( ULN ) ; SGOT/SGPT &lt; 5 ULN ; AP &lt; 5 ULN Life expectancy &gt; 12 week . Males reproductive potential must agree use effective contraceptive method treatment end treatment five month . Signed informed consent . Affiliated Health Insurance regimen ( accord Public Health Law August 9 , 2004 ) . Included ELANONCOVAL study consider `` Fit '' geriatric evaluation Patients nasopharyngeal cancer , paranasal sinus , cervical lymph node metastasis unknown origin . Prior systemic chemotherapy squamous cell carcinoma head neck , except give part multimodal treatment locally advanced disease complete 6 month prior study entry . Prior antiEGFR therapy , except give association radiotherapy squamous cell carcinoma head neck complete 12 month prior study entry . Surgery ( exclude prior diagnostic biopsy ) irradiation within 4 week study entry . Brain metastasis Active infection include tuberculosis HIV infection . Severe uncontrolled cardiovascular disease ( congestive heart failure NYHA III IV ) , unstable angina pectoris , history myocardial infarction within last twelve month , significant arrhythmia Concomitant immunotherapy antitumoral hormonotherapy . Requirement treatment prohibit concomitant medication list SPC Cetuximab Methotrexate . In particular , acetylsalicylic acid use analgesic , antipyretic antiinflammatory dos ( see Section 6.3.2 ) . Malignancies within 5 year prior randomization , exception adequately treat basal squamous cell skin cancer carcinoma situ cervix Known allergic hypersensitivity cetuximab know positive result test IgE antibody cetuximab ( α13galactose ) and/or methotrexate excipients . Other severe acute chronic psychiatric medical condition , significant laboratory abnormality require investigation may cause undue risk patient 's safety , inhibit protocol participation , interfere interpretation study result , judgment investigator would make patient inappropriate entry study</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>